Business Context and Reporting Period
Filing: Form 10-Q for the quarter and six months ended June 30, 2020. The provided filing identifies the registrant as Seneca Biopharma, Inc. (formerly Neuralstem, Inc.), not Palisade Bio, Inc.; this company-name discrepancy should be verified.
Seneca was a clinical-stage biopharmaceutical company developing neural stem-cell and small-molecule therapies. During the period, it was winding down existing NSI-566 and NSI-189 development programs, pursuing out-licensing or sale of those assets, and evaluating new acquisition or in-licensing opportunities. The company had seven full-time employees as of June 30, 2020.
Financial Highlights
| Metric | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2020 |
|---|---|---|
| Revenue | $2,500 | $8,520 |
| Operating expenses | $1,949,854 | $3,946,338 |
| Operating loss | $1,947,354 | $3,937,818 |
| Net loss | $1,950,941 | $9,526,159 |
| Net loss per share | $0.15 | $0.92 |
| Net cash used in operating activities | Not separately provided | $3,745,171 |
| Cash and cash equivalents at period end | Not applicable | $15,834,832 |
The company generated no revenue from product sales. Revenue consisted primarily of intellectual-property licensing fees and small royalty amounts related to a prior patent settlement. Profitability and meaningful product revenue had not been achieved.
At June 30, 2020, total assets were $17.1 million, total liabilities were $0.9 million, and stockholders’ equity was $16.2 million. Current liabilities were $0.7 million, while warrant liabilities were $62,623 and lease liabilities totaled approximately $163,000. The filing does not present traditional long-term debt as a material financing source.
Material Changes Versus Prior Comparable Period
- Second-quarter revenue declined to $2,500 from $7,894, primarily because the comparable 2019 period included $5,400 of royalty revenue from a prior patent settlement.
- Six-month revenue declined to $8,520 from $10,394.
- Second-quarter research and development expense decreased 53% to $446,032, reflecting the continued wind-down of clinical and small-molecule programs.
- Six-month research and development expense decreased 54% to $1.14 million.
- Second-quarter general and administrative expense increased 55% to $1.50 million, and six-month general and administrative expense increased 46% to $2.80 million. The increases reflected an enhanced management structure, including two executive officers and related consulting costs.
- Six-month net loss increased to $9.53 million from $4.55 million, principally because of a $5.62 million non-cash warrant-inducement expense recognized in 2020.
- Cash increased from $5.1 million at December 31, 2019 to $15.8 million at June 30, 2020, primarily from warrant exercises and equity financing.
- Common shares outstanding increased from 3.9 million at December 31, 2019 to 17.3 million at June 30, 2020, reflecting warrant exercises and equity issuances.
Cash Flow, Financing and Liquidity
- Operating activities used $3.75 million during the first six months of 2020, compared with $3.31 million in the prior-year period.
- Financing activities provided $14.47 million, including approximately $10.3 million from warrant exercises and $4.4 million of net proceeds from a May 2020 common-stock offering.
- In January 2020, warrant exercises generated approximately $6.7 million of net proceeds and resulted in replacement warrants.
- In May 2020, the company sold 5.0 million common shares for gross proceeds of $5.0 million and issued placement-agent warrants to purchase 400,000 shares.
- Management expected existing cash to fund the current operating plan for more than 12 months after the filing. However, the company stated that substantial doubt remained regarding its ability to continue as a going concern because additional capital is required for operations, acquisitions, in-licensing and development activities.
Outlook, Commentary and Risks
Management expected research and development spending to continue decreasing as existing programs were wound down and potential partners were sought. Spending could increase materially if the company successfully acquired or in-licensed new technologies. The company did not expect to become profitable in the next several years and had no commitments for future funding.
Management intended to seek financing through equity or debt offerings, licensing arrangements, collaborative transactions, asset sales, grants or combinations of these sources. Failure to obtain financing could require the company to curtail or discontinue operations, delay or stop clinical trials, license assets on unfavorable terms, or seek bankruptcy protection.
- COVID-19 could disrupt clinical trials, vendors, contract research organizations, contract manufacturers and access to capital; management stated that the medium- and long-term effects could be material.
- The company had received Nasdaq notices concerning noncompliance with the $1.00 minimum bid-price requirement and audit-committee composition requirements. The bid-price compliance deadline was December 10, 2020, and the audit-committee cure period was expected to expire no later than September 22, 2020.
- Existing programs remained subject to clinical, regulatory, manufacturing, intellectual-property and commercialization risks. NSI-189 had not met its primary efficacy endpoint in a Phase 2 major-depressive-disorder trial.
- The company had substantial accumulated losses, no commercial product revenue, limited personnel and dependence on future financing and successful licensing or acquisition activity.
- There were no reported legal proceedings as of the filing date.
Most Important Facts to Verify
- Confirm that the filing belongs to Seneca Biopharma, Inc. rather than Palisade Bio, Inc.; the supplied metadata and filing registrant do not match.
- Verify the company’s post-filing Nasdaq compliance status, including bid-price and audit-committee requirements.
- Assess the sustainability of the $15.8 million cash balance against quarterly operating cash burn and the company’s stated need for additional capital.
- Review dilution from the 17.3 million common shares outstanding, approximately 4.9 million outstanding warrants, options, preferred-stock conversion rights and other reserved shares.
- Evaluate whether any licensing, acquisition or out-licensing transactions were completed after June 30, 2020; the filing reported no committed future funding or completed new-asset transaction.
- Review subsequent filings for changes to the going-concern assessment, COVID-19 effects, clinical-program status and financing activity.